Verismo Therapeutics

About:

Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.

Website: https://verismotherapeutics.com

Twitter/X: VerismoTx

Top Investors: ScaleReady, BRV Capital Management, Hong Leong Bank, DongKoo Bio&Pharma

Description:

Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer. Verismo’s cellular therapy, known as KIR-CAR, is designed to provide a “natural stimulation” to T cells without triggering the T-cell exhaustion for the treatment of solid tumors. The lead therapy candidates in preclinical development are targeting pancreatic cancer, mesothelioma, and ovarian cancer.

Total Funding Amount:

$40.2M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Philadelphia, Pennsylvania, United States

Founded Date:

2020-01-01

Contact Email:

info(AT)verismotherapeutics.com

Founders:

Bryan Kim, Donald L. Siegel, Michael C. Milone

Number of Employees:

1-10

Last Funding Date:

2024-09-17

IPO Status:

Private

Industries:

© 2025 bioDAO.ai